Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


18.03.2019

1 Ann Oncol
2 BMC Cancer
1 Cancer Res
6 Gynecol Oncol
1 Int J Cancer
1 Int J Oncol
1 Lancet Oncol
1 Obstet Gynecol
4 Oncogene
1 Oncol Rep
1 Proc Natl Acad Sci U S A


   Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Oncol

  1. JOLY F, Ahmed-Lecheheb D, Kalbacher E, Heutte N, et al
    Long-term fatigue and quality of life among epithelial ovarian cancer survivors: A GINECO case/control VIVROVAIRE I Study.
    Ann Oncol. 2019 Mar 9. pii: 5372686. doi: 10.1093.
    PubMed     Text format     Abstract available


    BMC Cancer

  2. GAO C, Yao H, Liu H, Feng Y, et al
    TM4SF1 is a potential target for anti-invasion and metastasis in ovarian cancer.
    BMC Cancer. 2019;19:237.
    PubMed     Text format     Abstract available

  3. FANG C, Zhao L, Chen X, Yu A, et al
    The impact of clinicopathologic and surgical factors on relapse and pregnancy in young patients (</=40 years old) with borderline ovarian tumors.
    BMC Cancer. 2018;18:1147.
    PubMed     Text format     Abstract available


    Cancer Res

  4. NATARAJAN S, Foreman KM, Soriano MI, Rossen NS, et al
    Collagen remodeling in the hypoxic tumor-mesothelial niche promotes ovarian cancer metastasis.
    Cancer Res. 2019 Mar 12. pii: 0008-5472.CAN-18-2616.
    PubMed     Text format     Abstract available


    Gynecol Oncol

  5. LAVIE O, Chetrit A, Novikov I, Sadetzki S, et al
    Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer.
    Gynecol Oncol. 2019 Mar 11. pii: S0090-8258(19)30132.
    PubMed     Text format     Abstract available

  6. FOOTE JR, Secord AA, Liang MI, Ehrisman JA, et al
    Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.
    Gynecol Oncol. 2019;152:445-451.
    PubMed     Text format     Abstract available

  7. TAYLOR JS, Zhang N, Rajan SS, Chavez-MacGregor M, et al
    How we use hospice: Hospice enrollment patterns and costs in elderly ovarian cancer patients.
    Gynecol Oncol. 2019;152:452-458.
    PubMed     Text format     Abstract available

  8. KWON JS, Tinker AV, Hanley GE, Pansegrau G, et al
    BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer.
    Gynecol Oncol. 2019;152:459-464.
    PubMed     Text format     Abstract available

  9. MEYER LA, Shi Q, Lasala J, Iniesta MD, et al
    Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery.
    Gynecol Oncol. 2019;152:501-508.
    PubMed     Text format     Abstract available

  10. RATNER E, Bala M, Louie-Gao M, Aydin E, et al
    Increased risk of brain metastases in ovarian cancer patients with BRCA mutations.
    Gynecol Oncol. 2019 Mar 12. pii: S0090-8258(19)30152.
    PubMed     Text format     Abstract available


    Int J Cancer

  11. CHEN HJ, Huang RL, Liew PL, Su PH, et al
    GATA3 as a master regulator and therapeutic target in ovarian high-grade serous carcinoma stem cells.
    Int J Cancer. 2018 Jul 14. doi: 10.1002/ijc.31750.
    PubMed     Text format     Abstract available


    Int J Oncol

  12. ZHANG W, Ou X, Wu X
    Proteomics profiling of plasma exosomes in epithelial ovarian cancer: A potential role in the coagulation cascade, diagnosis and prognosis.
    Int J Oncol. 2019 Mar 7. doi: 10.3892/ijo.2019.4742.
    PubMed     Text format     Abstract available


    Lancet Oncol

  13. GOURD E
    No benefit of lymphadenectomy for advanced ovarian cancer.
    Lancet Oncol. 2019 Mar 7. pii: S1470-2045(19)30140.
    PubMed     Text format    


    Obstet Gynecol

  14. DOTTINO JA, Moss HA, Lu KH, Secord AA, et al
    U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
    Obstet Gynecol. 2019 Mar 11. doi: 10.1097/AOG.0000000000003171.
    PubMed     Text format     Abstract available


    Oncogene

  15. GHANNAM-SHAHBARI D, Jacob E, Kakun RR, Wasserman T, et al
    PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma.
    Oncogene. 2018 Jan 30. pii: 10.1038/s41388-017-0040.
    PubMed     Text format     Abstract available

  16. RUSSO A, Czarnecki AA, Dean M, Modi DA, et al
    PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation.
    Oncogene. 2018 Jan 25. pii: 10.1038/s41388-017-0097.
    PubMed     Text format     Abstract available

  17. MITAMURA T, Pradeep S, McGuire M, Wu SY, et al
    Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP).
    Oncogene. 2018;37:722-731.
    PubMed     Text format     Abstract available

  18. LIU Y, Zhou H, Zhu R, Ding F, et al
    SPSB3 targets SNAIL for degradation in GSK-3beta phosphorylation-dependent manner and regulates metastasis.
    Oncogene. 2018;37:768-776.
    PubMed     Text format     Abstract available


    Oncol Rep

  19. KOBAYASHI H, Yamada Y, Kawahara N, Ogawa K, et al
    Integrating modern approaches to pathogenetic concepts of malignant transformation of endometriosis.
    Oncol Rep. 2019;41:1729-1738.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A


  20. Correction for Li et al., Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.
    Proc Natl Acad Sci U S A. 2019 Mar 11. pii: 1902633116.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: